Cardiac Arrest Treatment Market Size& Industry Outlook
The global cardiac arrest treatment market size reached US$ 36.18Billion with a rise of US$38.71Billion in 2024 and is expected to reach US$ 74.42Billion by 2033, growing at a CAGR of 7.5%during the forecast period 2025-2033.
Increased demand for life-saving medications like amiodarone and epinephrine is being driven by growing awareness campaigns and extensive CPR and AED training programs that improve survival rates in cardiac arrest situations. The availability of AEDs in workplaces and public areas guarantees quicker response, which increases the need for drug-based therapies. A major factor in the market's expansion is the aging of the world's population, which also puts older people at greater risk for conditions like heart failure, arrhythmias, and coronary artery disease. Increased life expectancy and increased readiness are two variables that together propel the global market for medications used to treat cardiac arrest.
Key Highlights
- North America dominates the cardiac arrest treatment market with the largest revenue share of 46.5% in 2024
- The Asia Pacific is the fastest-growing region in cardiac arrest treatment market was valued at 24.3% market share in 2024
- Based on drug class, the vasopressors segment led the market with the largest revenue share of 30.4% in 2024
- Top companies in the Cardiac Arrest Treatment Market include Pfizer Inc., Viatris Inc., Upsher-Smith Laboratories, LLC, McKesson Medical-Surgical Inc., Sanofi, Par Pharmaceutical, Bayer AG, Bristol-Myers Squibb, Janssen Pharmaceuticals, Neon Laboratories, and Amneal Pharmaceuticals LLC, among others.
Market Dynamics
Drivers:
Increasing incidence of cardiovascular diseases driving the cardiac arrest treatment market growth
The rising incidence of cardiovascular diseases (CVDs) is a primary driver of the global cardiac arrest treatment market. Because of the increased risk of sudden cardiac arrest caused by conditions like coronary artery disease, heart failure, arrhythmias, and myocardial infarction, there is a greater need for emergency pharmaceutical therapies such as epinephrine, amiodarone, lidocaine, and vasopressors. Prehospital drug delivery, standardized hospital procedures, and expanding patient populations all contribute to an increase in drug use. Additionally, the long-term usage of these drugs is expanded by post-resuscitation therapy and heightened cardiac care awareness.
For instance, according to recent WHO and CDC data, cardiovascular diseases (CVDs) remain the leading global cause of death, with an estimated 19.8 million deaths in 2022, accounting for 32% of all deaths worldwide. Of these, 85% were due to heart attacks and strokes. In the United States alone, about 805,000 people experience a heart attack each year, including 605,000 first-time cases and 200,000 recurrent cases, underscoring the urgent need for effective prevention and treatment strategies for cardiac arrest and related conditions.
Restraints:
Side effects and drug interactions are hampering the growth of the cardiac arrest treatment market
Side effects and drug interactions are significant challenges limiting the growth of the cardiac arrest treatment market. Healthcare professionals utilize drugs like epinephrine, amiodarone, and lidocaine—which are frequently used in cardiac arrest—with caution since they can produce adverse effects such bradycardia, hypotension, arrhythmias, and organ toxicity. Furthermore, a large number of patients have several underlying cardiovascular diseases, which raises the possibility of drug interactions that could worsen toxicity or decrease efficacy. Particularly in environments with limited resources, these safety issues call for close observation, specific training, and extra funding.
For instance, amiodarone, used for shock-resistant ventricular fibrillation, can cause hypotension, bradycardia, liver toxicity, and pulmonary complications. It interacts with anticoagulants, beta-blockers, and other antiarrhythmics, raising the risk of toxicity. Due to these risks, hospitals may limit its use, especially in elderly or polypharmacy patients. Careful monitoring is required.
For more details on this report, see Request for Sample
Segmentation Analysis
The global cardiac arrest treatment market is segmented based on drug class, route of administration, distribution channel, and region.
Drug Class:
The vasopressors segment from drug class is dominating the cardiac arrest treatment market with a 30.4% share in 2024
The vasopressors segment, particularly epinephrine, dominates the cardiac arrest treatment market due to its role as the first-line drug for both shockable and non-shockable rhythms. It enhances coronary and cerebral perfusion, improving survival during resuscitation. Unlike antiarrhythmics or beta-blockers, vasopressors are universally applicable in nearly all cardiac arrest scenarios. Their widespread use in hospitals, EMS, and prehospital care, combined with guideline recommendations from ACLS and ERC, drives high consumption.
For instance, in January 2022, Tiohundra Healthcare Company successfully completed a Phase 3 clinical trial evaluating the use of vasopressin and steroids in addition to adrenaline for the treatment of cardiac arrest.
Route of Administration:
The intravenous segment is estimated to have a 61.3% of the cardiac arrest treatment market share in 2024
The intravenous (IV) segment dominates the cardiac arrest treatment market due to its rapid, reliable, and guideline-endorsed delivery of emergency drugs such as epinephrine, amiodarone, vasopressin, and lidocaine. IV administration allows medications to enter systemic circulation immediately, which is critical during life-threatening cardiac events. It is widely accessible in hospitals, ambulances, and prehospital care, making it the primary route in resuscitation. Alternative routes like intraosseous and endotracheal are used only when IV access is difficult, limiting their market share.
For instance, in March 2025, Oregon Health and Science University concluded a Phase 3 clinical study assessing the efficacy and safety of early intravenous amiodarone administration in patients experiencing shockable cardiac arrest.
Geographical Analysis
North America is expected to dominate the global cardiac arrest treatment market with 46.5% in 2024.
North America is expected to dominate the global cardiac arrest treatment market due to its high prevalence of cardiovascular diseases and advanced healthcare infrastructure. Hospitals and EMS widely adopt guideline-recommended drugs such as epinephrine, amiodarone, and vasopressin, with rapid intravenous administration ensuring effective resuscitation. The region hosts numerous clinical trials, accelerating the adoption of innovative therapies. Fast regulatory approvals from the FDA and Health Canada, along with high healthcare expenditure and public awareness initiatives like CPR training and AED availability, further strengthen market growth.
Owing to the factors like regulatory approvals,for instance, in November 2024, the FDA approved landiolol (Rapiblyk) for the treatment of atrial fibrillation and atrial flutter in the critical care setting. Landiolol is a highly selective beta-1 blocker that enables rapid management of heart rate with minimal reduction of blood pressure, addressing an important need in cardiac health management.
Europe is the second region after North America, which is expected to dominate the global cardiac arrest treatment market with 32.5% in 2024.
Europe is a key market for cardiac arrest treatment, second only to North America, driven by advanced healthcare infrastructure, robust EMS systems, and widespread adoption of drugs like epinephrine, amiodarone, and vasopressin. Rising cardiovascular disease prevalence, government-supported CPR and AED programs, and growing public awareness are fueling demand for effective cardiac arrest therapies across hospitals and prehospital care settings.
The region is also witnessing increasing adoption of advanced cardiac monitoring and emergency response technologies, as hospitals and EMS prefer real-time, non-invasive, and telemedicine-integrated solutions. Countries such as Germany, the UK, France, and Spain lead adoption due to strong healthcare infrastructure, reimbursement support, and specialized cardiac care centers, while Eastern and Southern Europe are gradually expanding access as healthcare modernization progresses.
Europe’s commitment to digital health innovation, increased research funding, and the shift toward patient-centric emergency care positions it as a key growth region for cardiac arrest treatment and monitoring solutions in the coming years.
The Asia-Pacific cardiac arrest treatment market was valued at 24.3% market share in 2024
Asia-Pacific is projected to be the fastest-growing region in the cardiac arrest treatment market, driven by rising cardiovascular disease prevalence and increasing awareness of emergency care. The region has a large patient pool, with countries like India and China experiencing high rates of heart disease, yet limited access to timely interventions creates strong growth potential as healthcare infrastructure and emergency response capabilities expand.
For instance, according to the Indian Heart Association, sudden cardiac arrest (SCA) claims more than 7 lakh lives annually, making it one of the leading causes of death in the country. Despite its prevalence, cardiac arrest often goes undiagnosed, as many people confuse it with a heart attack. The sudden and unpredictable nature of the condition makes it particularly dangerous.
Governments and healthcare providers are increasingly investing in digital health and telemedicine initiatives, supporting the effective administration and monitoring of cardiac arrest drugs, particularly in rural and underserved areas. Supportive regulatory reforms in countries such as Japan, South Korea, and Australia are facilitating faster approval and adoption of life-saving drugs like epinephrine, amiodarone, and vasopressin. Additionally, growing awareness, improved distribution channels, and initiatives to ensure timely intravenous or intraosseous delivery are enhancing access to these critical therapies, driving growth in the cardiac arrest treatment drugs market across the region.
Competitive Landscape
Top companies in the Cardiac Arrest Treatment Market include Pfizer Inc., Viatris Inc., Upsher-Smith Laboratories, LLC, McKesson Medical-Surgical Inc., Sanofi, Par Pharmaceutical, Bayer AG, Bristol-Myers Squibb, Janssen Pharmaceuticals, Neon Laboratories, and Amneal Pharmaceuticals LLC, among others.
Pfizer Inc.: Pfizer Inc., a global biopharmaceutical leader, offers cardiovascular drugs relevant to cardiac arrest management, including Tikosyn (dofetilide) and Corvert (ibutilide) for arrhythmia control, and Vyndaqel (tafamidis) for amyloid cardiomyopathy. While not directly targeting cardiac arrest, Pfizer’s portfolio supports treatment of underlying conditions that can trigger life-threatening events.
Market Scope
| Metrics | Details | |
| CAGR | 7.5% | |
| Market Size Available for Years | 2022-2033 | |
| Estimation Forecast Period | 2025-2033 | |
| Revenue Units | Value (US$ Mn) | |
| Segments Covered | Drug Class | Vasopressors, Beta Blockers, Anti-Arrhythmic Drugs, Anticholinergic Drugs, Corticosteroids, Fibrinolytic Drugs and Other |
| Route of Administration | Intravenous, Oral and Other | |
| End User | Hospital Pharmacies, Retail Pharmacies, Online Pharmacies | |
| Regions Covered | North America, Europe, Asia-Pacific, South America and the Middle East & Africa | |
The Global Cardiac Arrest Treatment Market report delivers a detailed analysis with 57 key tables, more than 65visually impactful figures, and 159 pages of expert insights, providing a complete view of the market landscape.
Suggestions for Related Report
For more pharmaceutical-related reports, please click here
